Axys Pharmaceuticals, Inc.

Merck Canada Inc.

Merck Sharp + Dohme Corp.

Merck Frosst Canada, Inc.

Merck Frosst Canada & Co.

The Royal Institution for the Advancement of Learning/mcgill University

Vouy-Linh Truong

Cheuk K Lau

Michel Therien

Jacques Yves Gauthier

Serge Leger

Cameron Black

Chun Sing Li

Christophe Mellon

Dan McKay

Michael J Green

Bernard Hirschbein

James T Palmer

Christopher I Bayly

Chitra Baskaran

James William Janc

Michel L Tremblay

Claudia Penafuerte

Matthew Feldhammer

George Zogopoulos

Sheldon Crane

Michael John Boyd

Carmela Molinaro

Brian P Kennedy

Amelie Roy

Brian Kennedy

Compounds of Formula I are disclosed wherein R, R, R, R, R, R, R, R, R, R, R, Rand Rare defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. 

HIV protease inhibitors

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

Cathepsin cysteine protease inhibitors

Growing community of inventors

Pierrefonds, Canada

Vouy-Linh Truong